![Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment](https://pub.mdpi-res.com/cells/cells-10-00323/article_deploy/html/images/cells-10-00323-g001.png?1612516155)
Cells | Free Full-Text | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
![JPM | Free Full-Text | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis JPM | Free Full-Text | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis](https://www.mdpi.com/jpm/jpm-09-00046/article_deploy/html/images/jpm-09-00046-g001.png)
JPM | Free Full-Text | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
![Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram](https://www.researchgate.net/publication/221924296/figure/fig3/AS:667588631744528@1536176941819/Mechanism-of-action-of-rituximab-Rituximab-is-a-monoclonal-antibody-directed-against.png)
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
![Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet](https://www.thelancet.com/cms/asset/bf64c07e-1d5b-43c3-98df-5b977e6d8a6a/gr1.jpg)
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
The Risk of Hyperglycaemia with the use of Rituximab in Rheumatoid Arthritis. Results from a Meta-analysis of Randomised Clinica
![Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fncprheum0424/MediaObjects/41584_2007_Article_BFncprheum0424_Fig1_HTML.jpg)
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
![Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fncprheum0424/MediaObjects/41584_2007_Article_BFncprheum0424_Fig2_HTML.jpg)
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
![A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy](https://www.futuremedicine.com/cms/10.2217/imt-2022-0024/asset/images/medium/figure1.gif)
A review of the totality of evidence in the development of ABP 798, a rituximab biosimilar | Immunotherapy
![Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/57302335-10b7-4e3f-b402-4d25811a8f1f/ajt_1288_f3.gif)
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
![Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-017-0612-x/MediaObjects/12325_2017_612_Fig1_HTML.gif)